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Novel Potent Metallocenes against Liver Stage Malaria
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Tropicais, IHMT-Universidade Nova de Lisboa, Lisbon, Portugalc; Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California,
USAd; and iMed.UL, CECF, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugale
Novel conjugates of the antimalarial drug primaquine (compound 1) with ferrocene, named primacenes, have been synthesized
and screened for their activities against blood stage and liver stage malaria in vitro and host-vector transmission in vivo. Both
transmission-blocking and blood-schizontocidal activities of the parent drug were conserved only in primacenes bearing a basic
aliphatic amine group. Liver stage activity did not require this structural feature, and all metallocenes tested were comparable to
or better than primaquine in this regard. Remarkably, the replacement of primaquine’s aliphatic chain by hexylferrocene, as in
compound 7, led to a45-fold-higher level activity against liver stage parasitemia than that of primaquine.
Resistance to antimalarials, especially in Plasmodium falcipa-rum, is a serious problem that threatens to undermine the
efficacy of even the artemisinin components of new first-line
artemisinin-based combination therapies (ACTs) (5, 7, 24). In
addition to P. falciparum, Plasmodium vivax malaria is an
increasing source of concern (1, 3, 11, 12, 14, 21, 23, 28, 32, 34).
The benign nature once ascribed to P. vivax is being questioned, as
we have gained an appreciation of the potential for severe and
even fatal P. vivax malaria (1, 11). Furthermore, P. vivax is the
plasmodial species most adaptable to temperate climate condi-
tions (3, 14, 21). The biological robustness of P. vivax parasites is
also reflected in their ability to form hypnozoites, dormant liver
forms that can cause relapses after the initial eradication of blood
stage parasites (18, 33), a feature shared with Plasmodium ovale
(3). Importantly, hypnozoites elude the action of almost any avail-
able antimalarial drugs, which makes hypnozoite reservoirs a se-
rious obstacle to malaria eradication (33).
Recently, there has been new enthusiasm for malaria eradica-
tion. Eradication efforts will be greatly facilitated by the availabil-
ity of drugs that act against multiple stages of the parasite, includ-
ing the liver forms of all malaria parasites and the dormant liver
hypnozoites of P. vivax and P. ovale (3, 14, 33). Unfortunately,
primaquine (PQ) (compound 1) (Fig. 1) is currently the only
clinically available 8-aminoquinoline active against all liver stages
of plasmodia (3, 30). PQ also offers activity against gametocytes,
thereby blocking transmission to mosquitoes. However, PQ has
low oral bioavailability and is hemotoxic, causing hemolytic ane-
mia in glucose-6-phosphate dehydrogenase (G-6PD)-deficient
individuals after the primary induction of methemoglobinemia
(30). Many PQ derivatives have been developed over the past 2
decades, including tafenoquine and bulaquine, but none, except
for bulaquine in India, has yet been approved for clinical use (30).
With the aim of minimizing the drawbacks of PQ while conserv-
ing its valuable antimalarial properties, we recently developed
imidazoquines (Fig. 1, compound 2, where X is H or an amino
acid residue), which were shown to be promising leads for novel
transmission-blocking antimalarials, given their significant activ-
ity in blocking the transmission of Plasmodium berghei malaria
from mice to mosquitoes and their remarkable stability in physi-
ological media (2, 31). However, imidazoquines are less active
than PQ against liver stage parasites (31), which led us to seek
alternatives. Previous reports of enhanced antimalarial activity
upon the introduction of ferrocene-basedmoieties (4, 7, 9, 10) led
us to synthesize a new set of PQ metallocene derivatives, named
primacenes (compounds 3 to 8) (Fig. 1). These were screened for
their activities in vivo as transmission-blocking agents and in vitro
against liver stage P. bergheimalaria parasites. Encouraging results
included the discovery of a metallocene with a level of liver stage
activity about 45-fold higher than that of the parent drug.
MATERIALS AND METHODS
Chemistry. N-protected amino acids were purchased from Bachem
(Switzerland). Solvents of high quality and thin-layer chromatography
(TLC) aluminum foil plates covered with silica 60 F254 (0.25 mm) and
silica gel 60 (70 to 230 mesh; ASTM) for preparative column chromatog-
raphy were all obtained from Merck (VWR International, Portugal).
When required, solvents were previously dried with preactivated molec-
ular sieves (4 Å), also from Merck. Racemic primaquine bisphosphate
(product no. 160393) and all remaining chemicals were obtained from
Sigma-Aldrich (Germany).
General synthetic procedures and chromatographic/spectroscopic
data were reported elsewhere previously for all compounds (19), except
for compounds 4f, 4g, and 8, for which relevant procedures and data
are available upon request (www.fc.up.pt/pessoas/pgomes/Matos-et-al
_AAC_SuppInfo.pdf).
The purities of all compounds were confirmed to be at least 98%, as
determined by high-performance liquid chromatography (HPLC) using a
Merck Hitachi Elite LaChrom instrument equipped with an L-2130
pump, an L-2200 autosampler, and an L-2455 diode array detector. Sam-
ples were injected onto a Merck Purospher Star RP-18e 125-cm by
4.6-mm (5-m) column equipped with a Merck Lichrocart precolumn
(Merck, Germany). Elution programs (eluent A consisted of H2O with
0.05% trifluoroacetic acid [TFA]; eluent B consisted of acetonitrile with
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FIG 1 Synthetic routes for primacenes 3 to 8. (i) Ferrocene-carboxylic acid (FcCOOH) (1molar equivalent, eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC.HCl) (1.1 eq.), triethylamine (TEA) (1.1 eq.), and dry dichloromethane (DCM) for 90 min in an ultrasound bath (USB) at room
temperature (RT), to give compounds 3, 5, and 6 (15) (a) or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) (1 eq.),
N-ethyl-N,N-diisopropylamine (DIEA) (2 eq.), and dry DCM at 0°C at RT for 24 h, to give compounds 4a to 4g. (ii) N-tert-Butoxycarbonyl-protected amino
acid succinimidyl ester (Boc-AA-OSu) (1.1 eq.), TEA (1.1 eq.), and dry DCM for 24 h at RT. (iii) Neat trifluoroacetic acid (TFA) for 30 min at RT and then 30%
aqueous (aq.) Na2CO3 dropwise to pH 11, followed by extraction with DCM. (iv) Dry acetone (2 eq. per day), 3-Å molecular sieves, and refluxing methanol for
3 days. (v) Same as described above for step ii but using Boc-Gly-OSu. (vi) SnCl2 (5 eq.) and dropwise concentrated HCl for 24 h at RT and then 8M aq. NaOH
dropwise to pH 11, followed by extraction with DCM (15). (vii) 6-Bromohexylferrocene (0.6 eq.) and TEA at 120°C for 24 h.
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0.05% TFA) were as follows: 45 to 60% solvent B in solvent A (0 to 10
min), 60% solvent B in solvent A (10 to 18 min), 60 to 100% solvent B in
solvent A (18 to 19 min), and 100% solvent B in solvent A (19 to 23 min)
for compound 4 and 70 to 100% solvent B in solvent A (0 to 5 min) and
100% solvent B in solvent A (5 to 15 min) for compound 8. Nuclear
magnetic resonance (NMR) spectra of compounds dissolved in either
deuterated chloroform (CDCl3) or hexadeuterated dimethyl sulfoxide
(DMSO-d6), containing tetramethylsilane (TMS) as an internal refer-
ence, were acquired on a Bruker AMX-300 spectrometer. Mass spectrom-
etry (MS) was performed by use of an electrospray ionization-ion trap
(ESI-IT) technique with a Finnigan Surveyor LCQDeca XPMax quadru-
pole mass spectrometer.
Biology. (i) In vivo transmission-blocking activity assays. BALB/c
mice were infected by intraperitoneal inoculations of 107 erythrocytes
parasitized with a green fluorescent protein (GFP)-expressing strain of P.
berghei ANKA. After 4 days, the presence of gametocytes was observed by
the microscopic observation of Giemsa-stained blood films and microg-
amete exflagellation. For each compound and PQ, mice were randomly
separated into groups of three animals, and each group was treated by the
intraperitoneal administration of one single dose of each compound and
PQ (10 and 50 mol/kg of body weight in inoculation volumes of 0.1 to
0.2 ml; controls consisted of infected mice given a phosphate-buffered
saline [PBS] solution). Two hours after administration, mice were anes-
thetized and placed on top of individual cages containing ca. 50 glucose-
starved Anopheles stephensi female mosquitoes, which were allowed to
feed for 1 h. After the bloodmeal, unfed femalemosquitoes were removed
from each cage. Ten days after the bloodmeal, mosquitoes were dissected
for the microscopic detection of oocysts in midguts.
(ii) In vitro blood-schizontocidal activity assays. In vitro blood-
schizontocidal activity assays were conducted as previously reported (31).
Briefly, synchronized ring stage W2 strain P. falciparum parasites were
cultured with multiple concentrations of test compounds (added from
1,000 stocks in DMSO) in RPMI 1640mediumwith 10%human serum
or 0.5% Albumax serum substitute. After 48 h of incubation, when con-
trol cultures contained new rings, parasites were fixed with 1% formalde-
hyde in PBS (pH 7.4) for 48 h at room temperature (RT) and then labeled
with YOYO-1 (1 nM; Molecular Probes) in 0.1% Triton X-100 in PBS.
Parasitemias were determined from dot plots (forward scatter versus flu-
orescence) acquired on a FACSort flow cytometer using CELLQUEST
software (Becton Dickinson). Fifty-percent inhibitory concentrations
(IC50s) for growth inhibition were determined from plots of percentages
of the control parasitemia relative to the inhibitor concentration by use of
GraphPad Prism software. In each case, the goodness of the curve fit was
documented by R2 values of0.95.
(iii) In vitro Plasmodium liver stage infection assays. The inhibition
of liver stage infection was determined by measuring the luminescence
intensity in Huh-7 cells infected with a firefly luciferase-expressing P.
berghei line, PbGFP-Luccon, as previously described (27). Huh-7 cells, a
human hepatoma cell line, were cultured in RPMI 1640 medium supple-
mented with 10% (vol/vol) fetal calf serum, 1% (vol/vol) nonessential
amino acids, 1% (vol/vol) penicillin-streptomycin, 1% (vol/vol) glu-
tamine, and 10mMHEPES (pH 7) andmaintained at 37°C with 5%CO2.
For infection assays, Huh-7 cells (1.2 104 cells per well) were seeded
into 96-well plates the day before drug treatment and infection. The me-
dium in the cells was replaced with medium containing the appropriate
concentration of each compound approximately 1 h prior to infection
with sporozoites freshly obtained through the disruption of the salivary
glands of infected femaleAnopheles stephensimosquitoes. The addition of
sporozoites was followed by centrifugation at 1,700 g for 5 min. At 24 h
postinfection, the medium was replaced with fresh medium containing
the appropriate concentration of each compound. The inhibition of par-
asite development was measured 48 h after infection. The effect of the
compounds on the viability ofHuh-7 cells was assessed by theAlamarBlue
assay (Invitrogen, United Kingdom) according to the manufacturer’s
protocol.
RESULTS
Chemistry. Primacenes were prepared, as depicted in Fig. 1, ac-
cording to previously described methods (19). Detailed synthetic
and spectroscopic data on these compounds were previously re-
ported (19), except for primacenes 4f, 4g, and 8, forwhich relevant
data are available upon request. In all cases, target compounds
were successfully isolated with a high level of purity, and their
structures were conveniently confirmed.
All compounds whose synthesis involved the coupling of race-
mic primaquine to enantiomerically pure L-amino acids (com-
pounds 4b to 4g) were isolated as mixtures of coeluting diaste-
reomers. All attempts to separate the two diastereomers of
compounds 4b to 4g using column chromatography, flash chro-
matography, and preparative TLC were unsuccessful.
Also, reverse-phase HPLC using Merck RP-8 and RP-18 col-
umns (both 125 and 250 mm) consistently gave single peaks for
derivatives 4b to 4g (not shown). Similar observations were re-
ported previously for the N-aminoacyl-primaquine precursors
(2, 31).
Biology. (i) In vivo transmission-blocking activity. The abil-
ities of primacenes 3, 4a, 4f, 4g, 6, and 8 to inhibit the sporogonic
cycle of plasmodia within the mosquito gut were studied by using
a model consisting of P. berghei ANKA-GFP-infected BALB/c
mice and Anopheles stephensi mosquitoes and were compared to
that of PQ (2, 31). Activities were measured at two different com-
pound concentrations by determining the percentage of mosqui-
toes with oocysts (infection rate) and themean number of oocysts
per infected mosquito (oocyst burden) (Table 1). Although this
model cannot distinguish gametocytocidal (inhibiting the stage
infective for mosquitoes) from sporontocidal (inhibiting mos-
quito stages) activity, it can clearly elucidate whether a compound
is effective at interrupting the transmission of infection from
mammalian hosts to mosquitoes. Of all the compounds tested,
only compounds 4a, 4f, and 8 showed an ability to decrease the
level of parasitemia in mosquitoes. Compound 8 was the only
compound, at a concentration of 50 mol/kg, able to completely
inhibit the sporogonic cycle of Plasmodium.
(ii) In vitro activity against blood stage P. falciparum. Com-
pounds 4f and 8 were evaluated for in vitro antiplasmodial activity
against chloroquine-resistantP. falciparum strainW2 (Table 1), as
previously described for compounds 3, 4a to 4e, and 7 (19). Unlike
what was found previously for compounds 3, 4a to 4e, and 7,
which were completely devoid of blood-schizontocidal activity
(19), compounds 4f (IC50  3.48 M) and 8 (IC50  1.25 M)
were moderately active, matching or even slightly outdoing the
activity of the parent drug (IC50 3.3 M).
(iii) Anti-Plasmodium liver stage activity. The ability of pri-
macenes to inhibit the development of P. berghei schizonts in
Huh-7 human hepatoma cells was assessed according to previ-
ously reported methods (27), as described in Materials and
Methods.
Figure 2 shows the results obtained upon the initial screening
of both cell viability and the inhibition of theP. berghei infection of
Huh-7 cells at two different concentrations. The parent drug, PQ,
was included at 15 M as a positive control. None of the com-
pounds affected cell confluence, as assessed by AlamarBlue fluo-
rescence, except for compound 8 at 2.5 M or above. At lower
concentrations, this compound was not active against liver stage
parasites. All other primacenes (compounds 3 to 7) were active
Matos et al.
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against liver stage P. berghei, in contrast to their behavior as
transmission-blocking or blood-schizontocidal agents. Pri-
macenes 4a, 4b, 4f, and 5 presented activities similar to that of PQ,
while primacene 4c had a 2.5-fold-higher level of activity, and
primacene 7 had a 45-fold-higher level of activity (Table 1).
DISCUSSION
Concerning the ability of primacenes to block host-to-vector ma-
laria transmission, Table 1 shows that only compounds 4a, 4f, and
8 were able to decrease the level of parasitemia in mosquitoes.
However, the activity of compound 4amust be seen skeptically, as
there was no dose-effect dependency. In turn, both compounds 4f
and 8 showed dose-dependent activity, with compound 8 being
able to fully impair the parasite’s sporogonic cycle at 50 mol/kg,
performing better than the parent drug PQ at the same concen-
tration. The common feature of compounds 4f and 8 is the pres-
ence of a basic aliphatic amine group connected to a poly-
methylene chain: in compound 4f, this corresponds to the R1
lysine side chain [—(CH2)4NH2], whereas in compound 8, it cor-
responds to the PQ aliphatic amine bound to ferrocene through a
—(CH2)6— spacer. Transmission-blocking activity was lost if a
basic aliphatic amine was absent, as in compounds 3, 6, and 7, or
when this amine was not connected to a polymethylene chain, as
in compound 4g. Thus, it seems that the presence of a—(CH2)n—
NHR (where n is 1 and R is H or an alkyl group) motif is re-
quired for the preservation of transmission-blocking activity in
PQ-ferrocene conjugates.
Interestingly, a previously reported assessment of the activity
of primacenes 3, 4a to 4e, and 7 against blood stage P. falciparum
(chloroquine-resistant strainW2) also revealed that themoderate
activity of PQ against blood stage malaria was completely lost in
compounds lacking the basic aliphatic amine (19); in turn, the
present study (Table 1) showed that such blood-schizontocidal
activity was recovered in compounds 4f and 8, again with com-
pound 8 performing slightly better than the parent drug.
Overall, there is strong evidence that the absence of
—(CH2)n—NHR (where n is1 and R is H or an alkyl group) is
detrimental to the activity of primacenes against both host-to-
vector transmission and blood stage malaria parasites (Table 1).
The relevance for the PQ antimalarial activity of a basic amino
group linked to the 8-aminoquinoline core through a carbon
chain of 2 to 6 carbons was established long ago (20, 25, 30). In
fact, most PQ derivatives that have lately been evaluated in clinical
trials as antiparasitics have the parent drug’s aliphatic chain either
conserved (e.g., tafenoquine) or modified at the amine terminus
in a way that reasonably preserves its basicity (e.g., bulaquine or
sitamaquine) (30). Many reports from different research groups
have demonstrated that the antimalarial activity of PQ is not abol-
ished by the acylation of its primary amine, but in all cases, an-
other basic amine was present elsewhere in the new molecule (2,
TABLE 1 Antiplasmodial activities of primacenes 3 to 8e
Compound R1
Charton’s 
constants for R1
(ref. 6)
clogP for model
amides 9a–9fa
Transmission-blocking activity
(infection rate [%]) (mean oocyst
burden [no. of oocysts/infected
mosquito]SEM)b
Activity against blood
stage P. falciparum
W2 (IC50 [M])
Activity against liver
stage P. berghei
(IC50 [M])10 mol/kg 50 mol/kg
1 45.7 (8.8 3.40) 26.9 (10.0)d 3.3c 7.50
3 98.3 (46.5 6.10) 88.1 (57.9 8.10) 10c 1.74
4af H 0 0.93 33.8 (40.8 10.3) 41.8 (80.2 7.60) 10c 9.33
4b Me 0.52 0.52 ND ND 10c 6.46
4c iPr 0.76 0.28 ND ND 10c 3.09
4d iBu 0.98 0.74 ND ND 8.33c 1.90
4e Bzl 0.70 0.75 ND ND 10c 2.40
4f (CH2)4NH2 0.62 93.3 (106 4.40) 42.4 (26.0 4.40) 3.48 6.46
4g CH2NH2 68.2 (62.5 6.70) 73.2 (57.6 4.00) ND ND
5 ND ND 10c 7.41
6 75.6 (30.2 4.2) 86.7 (47.4 4.40) 10c 2.82
7 80.0 (70.7 10.3) 95.8 (85.1 7.70) 10c 0.17
8 65.2 (61.7 6.30) 0.00 (0.00) 1.25 ND
a Calculated logarithm of the partition coefficient; calculated by using the OSIRIS Property Explorer (http://www.organic-chemistry.org/prog/peo/).
b See the text.
c Data taken from reference 19.
d Only two data points were available.
e Primaquine (compound 1) is also included for comparison. ND, not determined.
f In 4a to 4g, R1 stands for amino acid side chain; H, hydrogen; Me, methyl; iPr, isopropyl; iBu, isobutyl; Bzl, benzyl.
FIG 2 Evaluation of the activities of primacenes 3 to 8 against P. berghei liver
stages. Shown are data for the screening of anti-infective activity (bars) and
toxicity to hepatoma cells (line with square markers).
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15–17, 26, 31). Therefore, structural requirements for the activity
of primacenes against both host-to-vector transmission and blood
stage malaria parasites fully agree with previously established
structure-activity relationships (SAR) for PQ. However, any SAR
on PQ-based structures must be taken cautiously, as (i) the mode
of action of PQ is not yet fully understood and (ii) most SAR
reported for PQ-related structures have been taken from in vitro
blood-schizontocidal activity assays (20, 25, 30) and cannot be
used to predict or explain the tissue-schizontocidal activities of
novel PQ derivatives. This is dramatically demonstrated by the
present work, where all primacenes, except for compound 8, were
found to be active against liver stage parasites (Table 1 and Fig. 2).
Therefore, the lack of structural requisites found to be crucial for
the action of primacenes as blood schizontocidals or transmission
blockers was not impeditive to the display of liver stage activity, in
some cases at a notably high level. In particular, the treatment of
infected Huh-7 cells with compound 7 led to a remarkably potent
inhibition of liver stage parasites, as shown in Fig. 2. This exciting
finding was confirmed by the subsequent determination of IC50s
(Table 1), which substantiated that all primacenes have activity
against liver stage parasites equal to or better than that of PQ.
Specifically, compared to PQ, primacenes 4a, 4b, 4f, and 5 were
comparable in activity; primacene 4c had a 2.5-fold-higher level of
activity; and primacene 7 had a 45-fold-higher level of activity
(Table 1).
Another interesting observation was that for the subfamily of
compounds 4a to 4f, where natural amino acids are used as spacers
between PQ and the ferrocenoyl group, the IC50s correlated with
the nature of the amino acid side chains (Fig. 3A). These data
suggest a near-linear dependency between IC50s and Charton’s
steric constants,  (6), for the hydrocarbon side chains present in
compounds 4a to 4e (H, Me, iPr, iBu, and Bzl); however, the phe-
nylalanine derivative compound 4e (Fig. 3A, dashed circle) falls
out of this linear correlation, which may indicate that side-chain
bulkiness is not the only structural factor affecting activity. In fact,
since bulkier hydrocarbon side chains are increasingly lipophilic,
compound activity may depend not (or not only) on their size but
(also) on their lipophilicity. In support of this hypothesis, clogP
values estimated for the model amides 9a to 9f (Fig. 3B), having
the same side-chain variation as that of primacenes 4a to 4f, were
found to correlate linearly (r2  0.96) with IC50s for these com-
pounds (Fig. 3B). It is interesting that we have previously found a
similar trend for compounds 4a to 4e in terms of their activities
against another PQ-sensitive pathogen, Pneumocystis jirovecii
(19).
The effect of ferrocene on the liver stage activity of primacenes,
compared to the parent drug, is not uniquely demonstrated by the
remarkable activity of compound 7: primacene 6 (IC50  2.82
M) is not only 2.6-fold more active than PQ (7.5 M) but also
3.5- to 11-foldmore active than similar imidazoquines 10 possess-
ing natural amino acids instead of the ferrocenoyl group (31) (Fig.
4). Thus, it is sensible to assume that iron must be an important
player in the tissue-schizontocidal activity displayed by pri-
macenes.
The antimalarial activities of other quinoline-derived metal-
locenes, as ferroquine, are thought to be multifactorial, including
the generation of reactive oxygen species (ROS), like hydroxyl
radicals, under the oxidizing conditions of the food vacuole of
blood stage parasites; these radicalsmay be produced by a Fenton-
like redox reaction, represented by equation 1 (10):
Fe2 H2O2→ Fe
3 HO HO· (1)
Although the mechanism of action of PQ has not yet been deter-
FIG 3 (A) Correlation between IC50s (liver stage activity) (Table 1) and Char-
ton’s steric parameters for amino acid side chains (R1) in compounds 4a to 4e.
(B) clogP values estimated for model amides 9a to 9f, whose side chains (R1)
match those of primacenes 4a to 4f.
FIG 4 General structures of imidazoquines.
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mined, the drug is known to interfere with electron transport in the
respiratory chain, possibly leading to oxidative stress and an impair-
ment of mitochondrial function (30). Therefore, it is reasonable to
hypothesize that a ferrocene-based moiety, as in primacenes, might
increase the generation of hydroxyl radicals in the liver, reinforcing
the ROS-related tissue-schizontocidal activity of PQ. In fact, using a
ferrocene-based compound as an iron donor, Moon et al. recently
established that iron potentiates acetaminophen-induced oxidative
stress and mitochondrial dysfunction in cultured primary mouse
hepatocytes, following earlier reports on the increased production of
hydroxyl radicals and lipid peroxidation in ratswith an ironoverload
in the liver (22). While this indicates that the presence of iron in
primacenes will eventually bring about a higher level of hepatotoxic-
ity than that of the parent drug PQ, it may also explain why pri-
macenes like primacene 7 are so good at killing liver stage malaria
parasites.Upcoming toxicological studieswill provide the grounds to
establish a useful therapeutic window for primacenes; also, bioavail-
ability studiesmustbeundertaken toconfirmourbelief that thesePQ
derivatives do not undergo themetabolic oxidative deamination that
underlies the low bioavailability of PQ (19, 31). It is possible that a
highly active primacene, such as compound 7, will exhibit a signifi-
cantly improved therapeutic index over that of PQ.
A future definition of therapeutic windows/indices for pri-
macenes is also relevant for what concerns PQ-induced hemotoxic-
ity: methemoglobinemia and hemolytic anemia are dose-limiting
side effects of PQ, which hold back its therapeutic use and efficacy.
The hemotoxicity of PQ arises from hydroxylated metabolites
suchasN-hydroxy-8-amino-6-methoxy-quinoline (MAQ-NOH)or
5-hydroxylated species, which tautomerize into hemotoxic quinone-
imines (30). To avoid the formation of the latter, much effort has
been put into the development of PQderivatives substituted at quin-
oline’s C-5, of which tafenoquine (TFQ) has been the emblematic,
but not perfect, example (29, 30). TFQ is a 5-phenoxyl derivative of
PQ with a longer half-life and lower toxicity than those of PQ but is
not devoid of hemotoxicity in vivo, so new 5-aryl analogues are now
being explored as TFQ surrogates (29). Also, as for PQ, TFQ is not
protected from undergoing oxidative deamination on its aliphatic
chain. In primacenes, quinoline’s C-5 is not substituted, so hemo-
toxic 5-hydroxylated metabolites can arise; however, such problem
would be minimized if the oral bioavailability of the primacenes is
confirmed to be significantly higher than that of PQ or TFQ. These
aspects remain to be evaluated for primacenes, but it is interesting
that novel bis(8-aminoquinolines) derived from PQ, bearing an un-
substituted quinoline C-5, have a negligible propensity to induce the
formation ofmethemoglobin, togetherwith an improved antimalar-
ial activity over that of PQ (17).
Furthermore, although themolecularmasses of someprimacenes
are above 500 Da, which is a bit high according to known ADMET
(adsorption-distribution-metabolism-excretion-toxicity) rules of
thumb (13),most promising compounds are close to (compound 8)
or even below (compound 7) this value; compared to the above-
mentioned promising bis(8-aminoquinolines), whose average mo-
lecular masses lie above 600 Da (17), primacenes have “more drug-
like” sizes.
In conclusion, we describe novel conjugates of PQwith ferrocene
that are superior to PQ against liver stage Plasmodium parasites. The
presence of an aliphatic basic amine linked to a polymethylene chain
was required for transmission-blockingandblood-schizontocidal ac-
tivity but not for liver stage activity. It remains to be determined
whether the liver stage activity of metallocenes as compound 7 will
affect P. vivax hypnozoites, since a suitable in vitro model of these
parasite forms for drug screening is still unavailable (8).Nonetheless,
the remarkably potent activity of compound 7 makes it a highly
promising lead for novel agents against liver stage plasmodia. To the
bestofourknowledge, these areunprecedentedfindings thatpave the
way toward the development of novel primaquine-derived metal-
locenes as highly potent agents against liver stage malaria.
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